SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
Vanessa C BrunettiPauline ReynierLaurent AzoulayOriana Hoi Yun YuPierre ErnstRobert W PlattKristian B FilionPublished in: Pharmacoepidemiology and drug safety (2021)
SGLT-2i are associated with a decreased rate of HCAP compared to DPP-4i, but not when compared to GLP-1 RA, among patients with type 2 diabetes.